Cat. No. | Product name | CAS No. |
DC67070 | Novartis patent anti-PMEL17 Featured | |
DC67071 | Genentech patent anti-Polyubiquitin Featured | |
DC67072 | Eureka patent anti-PRAME Featured | |
DC67073 | BAY-1158061 Featured | |
DC67074 |
Rolinsatamab
Featured
Rolinsatamab is a IgG1κ type chimeric antibody targeting to PRLR (prolactin receptor). Rolinsatamab can be conjugated with pyrrolobenzodiazepine (PDB) dimer SGD-1882 (HY-101127) via a cleavable maleimidocaproyl type linker, to form an antibody-drug conjugate, Rolinsatamab talirine. One Rolinsatamab talirine has an average of 2 site-specific drug attachment engineered cysteines (C242, C242'). The linker equips the valine-alanine dipeptide, as cathepsine B cleavage site. on an average of 2 site-specific drug attachment engineered cysteines (C242, C242'). |
2095467-30-2 |
DC67075 | Forerunner patent anti-Prominin-1 Featured | |
DC67076 | AGS-1C4D4 Featured | |
DC67077 |
Inclacumab
Featured
Inclacumab (Anti-Human selectin P Recombinant Antibody) is a human monoclonal IgG4 antibody selectively targets P-selectin with a Kd value of 9.9 nM. Inclacumab inhibits P-selectin glycoprotein ligand 1 (PSGL-1) mimetic peptide bind with P-selectin with an IC50 value of 1.9 μg/mL and strongly inhibits cell adhesion. |
1256258-86-2 |
DC67078 |
Neihulizumab
Featured
Neihulizumab (ALTB-168) is an immune checkpoint agonistic antibody that binds to human CD162 (PSGL-1), leading to downregulation of activated T-cells. Neihulizumab can be uesd for steroid-refractory acute graft-versus-host-disease (SR-aGVHD), psoriasis, psoriatic arthritis and ulcerative colitis research. |
2158362-38-8 |
DC67079 | AG02-ADC Featured | |
DC65219 |
ACT-777991
Featured
ACT-777991 is an orally active and selective CXCR3 antagonist. ACT-777991 has microsomes and hepatocytes stability across animal models. ACT-777991 inhibits the migration of activated T cells toward CXCL11. |
1967811-46-6 |